Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001 [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 2, 2004, Pages 761-764

  Violin, Michela ^a   Velleca, Rossella ^a   Cozzi Lepri, Alessandro ^b   Riva, Chiara ^a   Grossi, Paolo Antonio ^c   Carnevale, Giuseppe ^d   Rizzardini, Giuliano ^d   Petrelli, Enzo ^e   Perno, Carlo Federico ^f   Monforte, Antonella D'Arminio ^a   Balotta, Claudia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c OSPEDALE DI CIRCOLO   (Italy)

^d Bustoarsizio Hospital   (Italy)

^e SAN SALVATORE HOSPITAL   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT FAILURE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 2542427688     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200406010-00017     Document Type: Letter

References (14)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-1730.
2. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
3. Descamps D, Flandre P, Calvez F, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 2000;283:205-211.
4. Pomerantz RJ. Primary HIV-1 resistance: a new phase in the epidemic? JAMA. 1999;282:1177-1179.
5. Haase AT, Schacker TW. Potential for the transmission of HIV-1 despite highly active antiretroviral therapy. N Engl J Med. 1998;339:1803-1809.
6. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir Ther. 2000;5:33-40.
7. Little SJ, Holte S, Routy JP, et al. Antiretroviral drug-resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
8. Grant RM, Hecht F, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181-188.
9. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 2001;15:2287-2292.
10. Goudsmit J, Weverling GJ, van der Hoek L, et al. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. AIDS. 2001;15:2293-2301.
11. The Drug Resistance Mutations Group. Update on drug resistance mutations in HIV-1. Topics HIV Med. 2003;3:92-96.
12. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of virological failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing HAART: the I.Co.N.A. study. AIDS. 2004;18:227-235.
13. Ammaramond P, Cunningham P, Oelrichs R, et al. No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001. AIDS. 2003;17:264-267.
14. Blower SM. Transmission of zidovudine resistant strains of HIV-1: the first wave. AIDS. 2001;15:2317-2318.